

HARNESSING THE POTENTIAL OF THE INNATE IMMUNE SYSTEM FOR ONCOLOGY

NASDAQ: AFMD

January 2024

Forward-Looking Statements

This presentation and the accompanying oral commentary contain "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying oral commentary, including statements regarding our future financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "believe," "will," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "might," "approximately," "expect," "predict," "could," "potentially" or the negative of these terms or other similar expressions.

Forward-looking statements appear in a number of places throughout this presentation and the accompanying oral commentary and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, the potential of acimtamig, AFM24, AFM28 and our other product candidates, the value of our ROCK[®] platform, the safety and efficacy of our product candidates, the potential of the LuminICE-203 study design to support accelerated approval by the FDA, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our collaboration activities, our ability to develop commercial functions, clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the macroeconomic trends that may affect the industry or us, such as the instability in the banking sector experienced in the first quarter of 2023, impacts of the COVID-19 pandemic, the benefits to Affimed of orphan drug designation, the impact on our business by political events, war, terrorism, business interruptions and other geopolitical events and uncertainties, such as the Russia-Ukraine conflict and, the risks, fact that the current clinical data of acimtamig in combination with NK cell therapy is based on acimtamig precomplexed with fresh allogeneic cord blood-derived NK cells from The University of Texas MD Anderson Cancer Center, as opposed to Artiva's AlloNK and other uncertainties and other factors described under the heading "Risk Factors" in Affiimed's filings with the Securities and Exchange Commission (the "SEC").

Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our management's beliefs and assumptions only as of the date of this presentation. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

The information contained in this presentation is solely for the purpose of familiarizing recipients hereof with Affimed and should be considered in the context of Affimed's SEC filings (including its effective registration statement and related prospectus), Form 20-F and other documents Affimed has filed with the SEC) and other public announcements that Affimed may make, by press release or otherwise from time to time. You should read these filings for more complete information about Affimed. You may get these filings for free by visiting EDGAR or the SEC website at <u>www.sec.gov</u>. This presentation and information contained herein should not be construed as a solicitation or an offer to buy or sell any securities and should not be treated as giving investment advice to recipients. It is not targeted to the specific investment objectives, financial situation or particular needs of any recipient. It is not intended to provide the basis for any third-party evaluation of any securities or any offering of them and should not be considered as a recommendation that any recipient should subscribe for or purchase any securities.



Why Invest in Affimed Now? 3 Clinical Assets with Multiple Near-Term Milestones

Lead Asset - Acimtamig (AFM13) Demonstrated Unprecedented Efficacy Against CD30+ Lymphomas

Acimtamig + NK cells: entering late-stage clinical dev; addresses r/r HL and PTCL global population of 10k

- **Outstanding efficacy**: **97%** ORR and **78%** complete response rate in 32 late-stage HL patients (AFM13-104)
- Extraordinary safety profile: No CRS, GVHD or ICANS observed
- Ph 2 LuminICE-203 (Acimtamig + AlloNK[®]) first two cohorts dosing patients

Two Additional Clinical Assets

- Second program, AFM24, showed single agent activity including 2 PRs and multiple SDs in *EGFR*mut NSCLC
- AFM24 is being evaluated in combination with atezolizumab (AFM24-102) in a Ph 2 clinical trial in NSCLC; 4 responses* and 73% DCR NSCLC *EGFR*wt (n=15)
- **Third program**, AFM28 in AML, shows differentiated profile in vitro and in vivo; currently enrolling a Ph 1 monotherapy study

Multiple Upcoming Milestones; cash of €98m with runway into 2025				
Program	Milestone	Timing		
LuminICE-203	Initial data update	H1 2024		
AFM24-102	PFS data update from NSCLC EGFRwt cohort	H1 2024		
AFM24-102	Data update from NSCLC EGFRmut cohort	H1 2024		
AFM28-101	Progress updates from dose escalation study (safety, dose levels)	H1 2024		

Pipeline Strengthened by Key Partnerships





Affimed's Technology is the Most Advanced Platform Based on Specific Engagement of Innate Immune Cells

ROCK[®] Platform addresses key limitations of traditional mAbs or ADCs

The problem: mAbs inefficiently recruit patient's own NK cells and/or macrophages due to:

- Low binding affinity and specificity
- V/F polymorphism
- High requirement for target expression

Affimed's solution: ROCK[®] Platform specifically targets CD16A using our customizable ICE[®] (innate cell engager) molecules.

- ICE[®] molecules have high affinity to CD16A and bind at a novel epitope outside the IgG binding epitope
- ICE[®] therapies have shown to have a good safety and tolerability profile
- Capable of bivalent NK-cell binding and does not induce nonspecific NK-cell activation
- Binding not impacted by V/F polymorphism

ICE[®] versus NK cell engager (NKE)

AFMD has the most advanced platform based on specific engagement of innate immune cells – nearly 400 patients have been treated with our proprietary ICE[®] molecules to date


ICE[®] vs. NKE

	ICE®	NKE
Binding sites to tumor target	2	1
High affinity binding sites to NK cells	2	1
Monotherapy data	yes	yes
Combo data with NK cells	yes	no
Combo data with CPI	yes	no
Safety	yes	yes



A Growing Pipeline Poised to Advance the Treatment of Cancer

Candidate (Target)	Indication & Modality	Discovery	Ph. 1	Ph. 2a/b	Ph. 3	Recent / Upcoming Milestones
Acimtamig	CD30-positive lymphomas (LuminICE-203)			artiva	80	Study initiated; data update in H1 2024
(CD30)	CD30-positive lymphomas (AFM13-104)					Data update at ASH 2023
AFM24	Multiple solid tumors (AFM24-102)					Data presented Dec. 2023
(EGFR)	Multiple solid tumors (AFM24-103)					Data presented at ASCO Breakthrough
AFM28	Acute Myeloid Leukemia					Fourth dose cohort ongoing
(CD123)	Acute Myeloid Leukemia					Pre-IND
AFVT-2101 / AFM32 (FRα)	Solid tumors		R			Pre-IND
	Multiple indications		Genentech A Member of the Roche Group		Pre-IND	
Novel ICE®	Multiple indications					Pre-IND; wholly-owned
	Multiple indications					Pre-IND; wholly-owned
Monotherapy	Combination with Adoptive NK Cells (allogeneic) Combir	nation with anti-PD-	L1		




Acimtamig

ICE[®] for CD30+ Lymphomas



Acimtamig: Unique Mechanism of Action Addressing Significant Unmet Need with Large Market Opportunity

Acimtamig restores NK cell function to recognize CD30+ lymphomas




- Acimtamig redirects NK cells and macrophages to tumor cells by binding to CD16A on innate immune cells and CD30 on cancer cells
- Acimtamig activates NK cells and macrophages through CD16A to kill tumor cells via ADCC and ADCP, respectively

Unmet need and market opportunities for CD30+ lymphomas

- CD30+ lymphomas comprise different subtypes: HL, PTCL, CTCL, DLBCL and FL
- Initial focus of acimtamig development in R/R patients with HL and PTCL
- Current treatment options largely chemo-based with limitations on duration of response (DoR) and high toxicity
 - Despite limitations, there is a significant market opportunity: brentuximab vedotin (B.V.) annual revenue > \$1.3B in 2021 and growing



AFM13-104: Median EFS of 9.8 Months, Median DOR of 8.8 Months and 30% of Patients Remained in Remission for More than 12 Months





Acimtamig + NK Cells Shows Unprecedented ORR and CR Rates in Double Refractory HL Patients

- All patients were heavily pre-treated and doublerefractory to BV and CPIs
- All patients were refractory to their most recent treatment
- Well managed safety profile with no cases of CRS, ICANS or GVHD




	AFM13-104 (NK cell combo) HL patients @ RP2D
Number Treated	32
No. Prior Lines Therapy (range)	7 (1-13)
Prior BV	100%
Prior CPI	100%
Prior SCT	63%
Response to Most Recent Treatment	0%




Acimtamig + NK cells is the most promising therapy being studied in HL patients who are relapsed or refractory to BV & CPIs

LuminICE-203 Study Design: Aligned with FDA Feedback [to support potential accelerated approval]

PHASE 2 TRIAL, R/R HL (SIMON TWO-STAGE DESIGN)



STUDY TREATMENT REGIMEN, UP TO 3 CYCLES



Acimtamig + AlloNK[®] Cells: Ph 2 LuminICE-203 Study Data Expected in H1 2024

- Combination therapy of acimtamig + AlloNK will evaluate up to 134 r/r HL and 20 r/r PTCL patients
- Initial data evaluating active doses expected in H1 2024

- Primary endpoints: Assess the antitumor activity by objective response rate (ORR) including complete responses (CR) and partial responses (PR)
- Secondary endpoints: Assess efficacy, duration of response (DOR), safety and tolerability and immunogenicity of the combination therapy
- Includes an exploratory cohort of CD30-positive r/r PTCL patients



LuminICE-203 Builds on Strong Phase 1/2 Data with Accelerated Approval Potential Confirmed by FDA Interactions





Evolving HL Landscape with Unmet Needs

• There is a void of viable agents for r/r patients due to the emergence of patients who are double refractory to BV and CPIs



Remarkable Efficacy



LuminICE-203 Underway with FDA Fast Track Designation




Attractive Opportunity

- Acimtamig + NK cells have shown 97% ORR, 78% CR in r/r HL with a well manageable safety profile
- Study enrolling with dosing of first two cohorts underway
- Expect initial data update from run-in phase H1 2024
- Includes a PTCL cohort to establish POC
- Type C meeting achieved alignment on new cohort to assess contribution of components
- Acimtamig + AlloNK[®] has the potential to address a ~\$3 billion market opportunity in r/r HL & PTCL where new treatment options are needed



A Significant Opportunity Exists to Address R/R HL in the 7 Major Markets with Additional Potential in R/R PTCL

Cases and Percentage of R/R CD30+ HL in the 7 Major Markets (MM)*



CD30+ R/R HL


Acimtamig + NK cell combo:

- Addresses the challenges of R/R HL
- Initial market value in HL is in the <u>></u>3-line setting
- Additional HL value with earlier lines of treatment
- Market research indicating premium above CAR-T pricing

Data as of April 2023; *7MM include US, EU5 (France, Germany, Italy, Spain, United Kingdom), and Japan **Source: SEER, WHO Globocan, Global Data; Kantar; Affimed Internal Research

*** **Source:** SEER, WHO Globocan, Global Data; Kantar; Leukemia & Lymphoma Society; Lymphoma Research Foundation; Laribi, Oncologist. 2018 Sep; 23(9): 1039–1053.; Brossard, Blooc (2014) 124 (19): 2983–2986.; Sabattini, Haematologica. 2013 Aug; 98(8): e81–e82.; Savage, Blood. 2008 Jun 15;111(12):5496-504; Affimed Internal Research

Cases and Percentage of R/R CD30+ PTCL in the 7 Major Markets (MM)*




CD30+ R/R PTCL

Acimtamig + NK cell combo:

- Addresses R/R CD30+ PTCL
- Limited treatment options exist for R/R PTCL
- Market research indicating premium above CAR-T pricing





AFM24


ICE[®] in EGFR+ Solid Tumors



AFM24 is an EGFR/CD16A Tetravalent Bi-Specific Antibody with a Novel Approach to Treating EGFR-Expressing Solid Tumors



AFM24 with its differentiated mode of action unleashes the potential of Innate Immunity in treating EGFR-expressing solid tumor indications




Current standard of care drugs:

- Disruption of the EGFR signaling cascade
- P Resistance \rightarrow activation of alternate pathways / downstream mutations
- Dose-limiting toxicities

The promise of AFM24's differentiated MoA*:

- Docking to EGFR only, no dependence on EGFR signaling
- Efficacy toward cells with mutated EGFR-signaling pathway
- Activation and recruitment of both the innate and adaptive immune cells
- Differentiated safety profile



Tumor cell killing via ADCC / ADCP

Disclaimer: The image provides an overview of selected EGFR-targeting therapeutic agents and does not represent an exhaustive summary.

* ... Based on in vitro and in vivo data in mouse, and cynomolgus monkeys and early clinical data (Wingert et al. mAbs 2021;13: 1950264). **TKI** = tyrosine kinase inhibitor.



AFM24 Path Forward: NSCLC in Combination with Atezolizumab

AFM24, a first in class ICE[®] for EGFR-positive solid tumors

- Early clinical program:
 - Demonstrated **safety** as monotherapy and in combinations (NK, PD1)
 - Showed anti-tumor activity as a monotherapy and in combinations
 - Provided clinical validation that triggering innate
 immunity activates adaptive immunity
- Highest efficacy seen in NSCLC across a range of indications evaluated:
 - Data in NSCLC EGFRwt with AFM24 in combination atezolizumab is highly encouraging
 - Monotherapy activity seen in *EGFR*mut NSCLC led to inclusion in AFM24-102 trial

AFM24 in combination with atezolizumab has potential to demonstrate a meaningful clinical benefit with a favorable safety profile in both EGFRwt and EGFRmut NSCLC patient populations



AFM24-102 NSCLC *EGFR*wt Cohort Patient Characteristics & AFM24 Related Treatment-Emergent Adverse Events

Patient Characteristics NSCLC EGFRwt cohort	N=17*
Age (years) Median-Range	66 (45-75)
Sex n (%) • Male • Female	14 (82.4) 3 (17.6)
Race n (%) • White • Asian	8 (47.1) 9 (52.9)
ECOG PS (n, %) • 0 • 1	2 (11.8) 15 (88.2)
No. Prior Lines of treatment Median (range)	2 (1-5)
Prior CPI Response to CPI Refractory to CPI**	100% 4 PR / 7 SD 6

Most Relevant AFM24 Related Treatment Emergent Adverse Events NSCLC EGFRwt cohort	N=17
Asthenia G1	1 (1)
AST elevation G1 G2	2 (2) 1 (1)
ALT elevation G1 G2	3 (2) 2 (1)
Erythematous rash G1 G2	3 (3) 1 (1)
Infusion related reaction G1 G2 G3	3 (2) 2 (2) 1 (1)
AFM24 has demonstrated to be safe and we	- -


- AFM24 has demonstrated to be safe and welltolerated as both a monotherapy and in combination
- Combination with atezolizumab has not led to unexpected toxicity: Observed toxicity in line with toxicity profile of the individual agents

*Overall 17 pts were recruited into the cohort, 15 pts are included in the FAS (full analysis set) for efficacy as per protocol. **All patients ultimately had progressed on previous CPI treatment Data-cut for safety: 29-Oct-2023 done in preparation for Investigators brochure V 5.0



AFM24-102 NSCLC *EGFR*wt Expansion Cohort with Tumor Shrinkage in 7 Patients (47%)


Waterfall Plot for Best %-Change from BL in Sum of Longest Diameter (Investigator Assessment)



According to RECIST 1.1, a subsequent second scan is required for confirmation

* One additional patient (ES-002-3014 - not displayed in the waterfall plot) discontinued early and was not evaluable according to RECIST 1.1 # valid post-baseline efficacy scan according to RECIST 1.1

AFM24-102 NSCLC *EGFR*wt Expansion Cohort: Treatment Ongoing in 10 of 14 Evaluable Patients



According to RECIST 1.1, a subsequent second scan is required for confirmation * Early discontinuation

Patient deceased


Based on Rechallenge Data, Atezolizumab Monotherapy has Little to No Activity After Progression on CPI

Metric	Atezo Monotherapy ¹	
ORR	0-7%	
> mPFS	2.9-3.9 months	

It is unlikely the results in NSCLC EGFRwt are driven solely by atezolizumab

1. "Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies", ANTICANCER RESEARCH 39: 3917-3921 (2019), "Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review," Thoracic Cancer 11 (2020) 1927–1933







ICE[®] in AML



AFM28: AML Requires Novel Treatments with Strong Rationale and Well Tolerated Toxicity Profile



Significant market potential and high unmet need	Newly diagnosed AML: 42,000 annual incidence (7MM) High relapse rate: 60% of patients are primary refractory or relapse within 1 year R/R AML: 1-year OS: 29%, 5-year OS: 11%
Lack of effective treatments	Poor response to chemotherapy: Primary induction failures, early relapses Measurable Residual Disease: High rates of relapse Limited options for R/R AML
High toxicity of current treatment options	Primarily a disease of elderly, majority of patients cannot tolerate standard treatment Treatment-related deaths and poor quality of life from treatment-related toxicity



AFM28 is Designed to Improve Efficacy and Safety in AML to **Prevent or Delay R/R Disease**



AFM28 Shows differentiating preclinical efficacy and safety data	Monotherapy Establish a dosing regimen and assess safety and preliminary activity
 AFM28 poster presentations at ASH 2021, NK2022 and ASH 2022^{1,2} Selectively redirects NK cells to CD123+ leukemic cells and leukemic stem cells Potent induction of NK cell ADCC even at very low CD123 expression 	 Status Cleared 3rd dose cohort cleared without dose limiting toxicities Completed enrollment in 4th dose cohort
 Very low risk of CRS based on preclinical toxicity studies Specific high affinity binding to CD16A with prolonged NK cell surface retention 	NK cell combinations
 Potential for combination with off-the-shelf allogeneic NK cell therapy 	Status Study initiation planned as soon as feasible
 Jana-Julia Götz et al. AFM28, FM28, a Novel Bispecific Innate Cell Engager (ICE®), Designed to Selectively Re Myeloid Leukemia and Myelodysplastic Syndrome (ASH – American Society for Hematology Annual Meeting, D Jens Pahl et. al. Novel Bispecific Innate Cell Engager AFM28 in Combination with Allogeneic NK Cells for the T Myelodysplastic Syndrome (NK2022 – Society for Natural Immunity, May 2022) 	e-direct NK Cell Lysis to CD123 + Leukemic Cells in Acute ecember 2021) reatment of CD123+ Acute Myeloid Leukemia and

Program	Milestone	Timing
LuminICE-203	Data update from patients treated in cohorts 1-4	H1 2024
AFM24-102	PFS data update from NSCLC EGFRwt cohort	H1 2024
AFM24-102	Data update from NSCLC EGFRmut cohort	H1 2024
AFM28-101	Progress updates from dose escalation study (safety, dose levels)	H1 2024





Why Invest in Affimed Now? 3 Clinical Assets with Multiple Near-Term Milestones

Lead Asset - Acimtamig (AFM13) Demonstrated Unprecedented Efficacy Against CD30+ Lymphomas

Acimtamig + NK cells: entering late-stage clinical dev; addresses r/r HL and PTCL global population of 10k

- **Outstanding efficacy**: **97%** ORR and **78%** complete response rate in 32 late-stage HL patients (AFM13-104)
- Extraordinary safety profile: No CRS, GVHD or ICANS observed
- Ph 2 LuminICE-203 (Acimtamig + AlloNK[®]) first two cohorts dosing patients

Two Additional Clinical Assets

- **Second program**, AFM24, showed single agent activity including 2 PRs and multiple SDs in *EGFR*mut NSCLC
- AFM24 is being evaluated in combination with atezolizumab (AFM24-102) in a Ph 2 clinical trial in NSCLC; 4 responses* and 73% DCR NSCLC *EGFR*wt (n=15)
- Third program, AFM28 in AML, shows differentiated profile in vitro and in vivo; currently enrolling a Ph 1 monotherapy study

Multiple Upcoming Milestones; cash of €98m with runway into 2025				
Program	Milestone	Timing		
LuminICE-203	Initial data update	H1 2024		
AFM24-102	PFS data update from NSCLC EGFRwt cohort	H1 2024		
AFM24-102	Data update from NSCLC EGFRmut cohort	H1 2024		
AFM28-101	Progress updates from dose escalation study (safety, dose levels)	H1 2024		

Pipeline Strengthened by Key Partnerships







Thank you!

